Butyrate in the treatment of ulcerative colitis

Digestive and Liver Disease Supplements

Volumn 1, Issue 1, 2007, Pages 27-30

  Vernia, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Butyric acid; Therapy; Ulcerative colitis

Indexed keywords

BUTYRIC ACID; CYTOKINE; ENEMA; MESALAZINE; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INTESTINE ABSORPTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 64349116055     PISSN: 15945804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1594-5804(08)60008-X     Document Type: Review

References (23)

1. Roediger W. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 21 (1980) 739-748
2. D'Argenio G., Cosenza V., Sorrentini I., De Ritis F., Gatto A., Delle Cave M., et al. Butyrate, mesalamine, and factor XIII in experimental colitis in the rat: effects on transglutaminase activity. Gastoenterology 106 (1994) 399-404
3. Luhrs H., Gerke T., Muller J.C., Melcher R., Schauber J., Boxberge F., et al. Butyrate inhibits NF-kB activation in lamina propria macrophages in patients with ulcerative colitis. Scand J Gastroenterol 37 (2002) 458-466
4. Segain J.P., Raingeard D., Bourreille A., Leray V., Gervois N., Rosales C., et al. Butyrate inhibits inflammatory responses through NF-kB inhibition: implications for Crohn's disease. Gut 47 (2000) 397-403
5. Forest V., Pierre F., Bassonga E., Meflah K., Olivier C., and Menanteau J. Apc+/Min colonic epithelial cells express TNF receptors and ICAM-1 when they are co-cultured with large intestine intra-epithelial lymphocytes. Cell Immunol 223 (2003) 70-76
6. Ogawa H., Rafiee P., Fisher P.J., Johnson N.A., Otterson M.F., and Binion D.G. Butyrate modulates gene and protein expression in human intestinal endothelial cells. Biochem Biophys Res Commun 309 (2003) 512-519
7. Kiefer J., Beyer-Sehlmeyer G., and Pool-Zobel B.L. Mixtures of SCFA, composed according to physiologically available concentrations in the gut lumen, modulate histone acetylation in human HT29 colon cancer cells. Br J Nutr 96 (2006) 803-810
8. Velazquez O.C., Lederer H.M., and Rombeau J.L. Butyrate and the coloncyte. Implications for neoplasia. Dig Dis Sci 41 (1996) 727-739
9. Vernia P., Gnaedinger A., Hauck W., and Breuer R.I. Organic anions and the diarrhea of inflammatory bowel disease. Dig.Dis.Sci. 33 (1988) 1353-1358
10. Breuer R.I., Buto S.K., Christ M.L., Bean J.A., Di Paolo M.C., Vernia P., et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Dig Dis Sci 36 (1991) 185-187
11. Scheppach W., Sommer H., Kirchner T., Paganelli G.M., Bertram P., Christl S., et al. Effect of butyrate on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103 (1992) 51-56
12. Vernia P., Marcheggiano A., Caprilli R., Frieri G., Corrao G., Valpiani D., et al. SCFA topical treatment in distal ulcerative colitis. Aliment Pharm Ther 9 (1995) 309-313
13. Scheppach W., and German-Austrian SCFA Study Group. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. Dig Dis Sci 41 (1996) 2254-2259
14. Steinhart A.H., Hiruki T., Brzezinski A., and Baker J.P. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 10 (1996) 729-736
15. Breuer R.I., Soergel K.H., Lashner B.A., Christ M.L., Hanauer S.B., Vanagunas A., et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomized, placebo controlled trial. Gut 40 (1997) 485-491
16. Patz J., Jacobsohn W.Z., Gottschalk-Sabag S., Zeides S., and Braverman D.Z. Treatment of refractory distal ulcerative colitis with SCFA. Am J Gastroenterol 91 (1996) 731-734
17. Steinhart A.H., Brzezinski A., and Baker J.P. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 89 (1994) 179-183
18. Vernia P., Cittadini M., Caprilli R., and Torsoli A. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 40 (1995) 305-307
19. Vernia P., Monteleone G., Grandinetti G., Villotti G., Di Giulio E., Frieri G., et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine in active ulcerative colitis: A double-blind placebo-controlled study. Dig Dis Sci 45 (2000) 976-981
20. Gaudier E., Jarry A., Blottière H.M., Aubert J.P., Laboisse C., Cherbut C., et al. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiol Gastrointest Liver Physiol 287 (2004) G1168-G1174
21. Schauber J., Svanholm C., Termen S., Iffland K., Menzel T., Scheppach W., et al. Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. Gut 52 (2003) 735-741
22. Zapolska-Downar D., Siennicka A., Kaczmarczyk M., Kolodziej B., and Naruszewicz M. Butyrate inhibits cytokine-induced VCAM-1 and ICAM-1 expression in cultured endothelial cells: the role of NF-kappaB and PPARalpha. J Nutr Biochem 15 (2004) 220-228
23. Germann A., Dihlmann S., Hergenhahn M., Doeberitz H.K., and Koesters R. Expression profiling of CC531 colon carcinoma cells reveals similar regulation of beta-catenin target genes by both butyrate and aspirin. Int J Cancer 106 (2003) 187-197